Macrophage-centered therapy strategies: A promising weapon in cancer immunotherapy.

Asian journal of pharmaceutical sciences 2026
Open on PubMed

Macrophages are critical phagocytes in the immune system, and tumor-infiltrating macrophages can substantially influence the efficacy and prognosis of immunotherapy. Therefore, macrophages may serve as therapeutic targets for modulating the tumor immune microenvironment. Macrophage-based drug delivery systems have been extensively evaluated owing to their excellent biocompatibility, long half-life, and inherent ability to migrate and accumulate at sites of inflammation, such as tumors. Live macrophages and their membrane coatings contain abundant receptor proteins that facilitate payload transport across physiological barriers. In this review, we discuss strategies that utilize macrophages as targets and delivery carriers for cancer immunotherapy. Here, we summarize the different macrophage phenotypes, tumor-associated macrophage-targeting strategies, and biomimetic delivery carriers derived from macrophages used in immunotherapy. Overall, macrophage-centered strategies for cancer therapy hold considerable promise for clinical applications.

9 Figures Extracted
Figure 1
Figure 1 PMC
Fig. 1
Fig. 1 PMC
Development of macrophages-based DDSs in cancer immunotherapy. Macrophages were first discovered in 1882 in starfish hatchlings [ 15 ]. In 1891, Willi...
Fig. 2
Fig. 2 PMC
Biogenesis and phenotype plasticity of macrophages.
Fig. 3
Fig. 3 PMC
Classification of macrophages under cytokines and chemokines stimulations.
Fig. 4
Fig. 4 PMC
Primary TAM-targeting strategies include: regulation of phagocytic checkpoints, inhibiting macrophage recruitment, depletion of TAMs, and reprograming...
Fig. 5
Fig. 5 PMC
Diverse drug loading strategies employed by viable macrophages as carriers for drug delivery. (A) Direct incubation with chemotherapeutic agents; (B) ...
Fig. 6
Fig. 6 PMC
Schemes of macrophage membrane-mediated biomimetic nanocarriers. (A) Synthetic NPs derived from macrophages. They are assembled by synthesized phospho...
Fig. 7
Fig. 7 PMC
Illustration of the CAR-M architecture and its benefits in the treatment of solid tumors.
Fig. 8
Fig. 8 PMC
Application of macrophage-derived EVs in immunotherapy.